Q1 2025 Earnings Conference Call NASDAQ: EQIX Presented on April 30, 2025 © 2025 Equinix, Inc. Public Disclosure Statement Forward-Looking Statements Except for historical information, this presentation contains forward-looking statements which include words such as "believe," "anticipate," and "expect." These forward-looking statements involve risks and uncertainties that may cause Equinix's actual results to differ materially from the expectations discussed in such forward-looking statements. Factors that ...

© 2025 eBay | Business & Financial Highlights Q1'25 Disclosures This presentation contains non-9A4P measures relating to our performance. You can find the resonciliation of these measures, except for FK-Neutral basis, to the nearest co GAAP measures in the appendix at the end of this gresentation. All grount rates regresent vear-sent vear-sent vear-somparisons, except as otherwise noted. For rumbers in th provided on an "FX-Neutral" basis, we calculate the vear-over-vear impact of forceign curnency movement ...

F o u r t h Q u a r t e r 2 0 2 4 E a r n i n g s P r e s e n t a t i o n April 30, 2025 1 Disclaimers Forward-Looking Statements This presentation includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. KORE's actual results may differ from their expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Forward-looking statements ...

2024 Results and 2025 Outlook: A Point of Transformation April 2025 Disclaimer Cautionary Note Regarding Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding Nano's future growth, strategic plan and value to shareholders, Desktop Metal's strategic review process, and all other statements other than statements of historical fact that address acti ...

Financial Performance Highlights - Total revenues decreased by 8.3% year-over-year to $4.0 billion[10] - Adjusted Gross Profits increased by 2.3% year-over-year to $673 million[10] - Income from Operations increased significantly by 39.1% year-over-year to $177 million[10] - Net Income per Share increased by 42.3% year-over-year to $1.11[10] Segment Performance - NAST (North American Surface Transportation) adjusted gross profits increased by 5.3% year-over-year[14], with truckload AGP increasing by 6.9% to $252.0 million and LTL AGP increasing by 4.9% to $146.4 million[19] - Global Forwarding adjusted gross profits increased by 2.5% year-over-year[14], with ocean AGP increasing by 2.2% to $115.3 million and air AGP increasing by 7.1% to $32.3 million[28] - All Other & Corporate adjusted gross profits decreased by 13.0% year-over-year[14], with Other Surface Transportation AGP declining significantly by 74.1% due to the divestiture of the Europe Surface Transportation business[18, 34] Operational Improvements and Strategies - NAST gained market share in truckload and LTL, increasing AGP per shipment year-over-year through disciplined pricing and cost advantages[12] - Global Forwarding grew ocean volume year-over-year, with ocean and air AGP per shipment also increasing year-over-year[12] - The company is focused on streamlining processes, applying Lean principles, and leveraging generative AI to optimize costs and drive operating leverage[12]

Q3 Fiscal 2025 Earnings Quarter Ended March 31, 2025 • Reported April 30, 2025 These forward-looking statements are based on current information and expectations and involve a number of risks and uncertainties. Actual results may differ materially from those projected in such statements due to various factors, including but not limited to: the impact of tariffs on our business; our vulnerability to a weakening in the condition of the financial markets and the global economy; risks related to our internation ...

© 2025 Cognizant Forward-looking statements This earnings supplement includes statements that may constitute forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the accuracy of which is necessarily subject to risks, uncertainties and assumptions as to future events that may not prove to be accurate. These statements include, but are not limited to, express or implied forward-looking statements relating to our strategy, competitive p ...

Q2'25 FINANCIAL RESULTS Neil Barua CEO Kristian Talvitie CFO April 30, 2025 FORWARD LOOKING STATEMENTS This presentation includes forward looking statements regarding PTC's future financial performance, strategic outlook and expectations, anticipated future operations, expected effects of strategic investments and initiatives, and share repurchase expectations. Because such statements deal with future events, actual results may differ materially from those projected in the forward-looking statements. Inform ...

Standard Motor Products, Inc. 1st Quarter 2025 Earnings Call | April 30, 2025 1 Safe Harbor – Forward Looking Statements You should be aware that except for historical information, the matters discussed herein are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward looking statements, including projections and anticipated levels of future performance, are based on current information and assumptions and involve risks and uncertainties which may caus ...

Financial Performance & Guidance - Increased 2025 financial guidance by >20%[52] - 2025 revenue guidance is $725-$750 million, up from prior guidance of >$600 million[56] - Anticipated operating loss for 2025 is <$375 million, improved from prior guidance of <$495 million[56] - Cash and short-term investments stand at ~$1.9 billion[56] - Q1 2025 revenue was $132 million, including $76 million in commercial revenue and $56 million in R&D revenue[52] Product Launches & Pipeline - TRYNGOLZA generated over $6 million in net product sales in its first full quarter of launch[20,54] - TRYNGOLZA prescriptions are split ~60% commercial and ~40% government coverage[23] - Donidalorsen U.S approval PDUFA date is August 21, 2025[15] - Olezarsen sHTG Phase 3 (CORE and CORE2) data is expected in Q3 2025[15] - Median fasting baseline TG levels in CORE and CORE2 studies were 836 mg/dL and 749 mg/dL, respectively[40] - 84% of switch patients surveyed preferred Donidalorsen[46]